<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Toxoplasmosis in patients with HIV</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Toxoplasmosis in patients with HIV</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Toxoplasmosis in patients with HIV</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rajesh T Gandhi, MD, FIDSA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul E Sax, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 31, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Toxoplasmosis is the most common central nervous system infection in patients with the acquired immunodeficiency syndrome (AIDS) who are <strong>not</strong> receiving appropriate prophylaxis [<a href="#rid1">1,2</a>]. This infection has a worldwide distribution and is caused by the intracellular protozoan parasite, <em>Toxoplasma gondii</em>. Immunocompetent persons with primary toxoplasmosis are usually asymptomatic, and latent infection can persist for the life of the host. In immunosuppressed patients, especially patients with AIDS, the parasite can reactivate and cause disease, usually when the CD4 count falls below 100 cells/microL [<a href="#rid1">1,3,4</a>].</p><p>This topic will focus on the clinical manifestations, diagnosis, and treatment of toxoplasmosis in patients with HIV. A discussion of toxoplasmosis in immunocompetent hosts is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/120887.html" rel="external">"Toxoplasmosis: Acute systemic disease"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H878458677"><span class="h2">Transmission</span><span class="headingEndMark"> — </span>In humans, toxoplasmosis is typically acquired through ingestion of infectious oocysts, usually from soil or cat litter contaminated with feline feces, or undercooked meat from an infected animal. When humans ingest <em>T. gondii</em> oocysts, the organisms invade the intestinal epithelium and disseminate throughout the body. They then encyst in any type of nucleated cell and can lie dormant within tissues for the life of the host. A more detailed discussion on the transmission of toxoplasmosis is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/120887.html" rel="external">"Toxoplasmosis: Acute systemic disease"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Prevalence of infection</span><span class="headingEndMark"> — </span>The prevalence of infection with <em>T. gondii</em> varies substantially among different countries and ranges from approximately 11 percent in the United States to more than 80 percent in certain European, Latin American, and African countries [<a href="#rid5">5</a>]. In general, the seroprevalence of antibodies to <em>T. gondii</em> among patients with HIV mirrors the rate of seropositivity in the general population and is not related to owning a cat [<a href="#rid6">6,7</a>]. However, the prevalence may be associated with age. As an example, in a study of women with HIV in the United States, those who were ≥50 years old were more likely to be seropositive compared with younger women (odds ratio 2.4, 95% CI 1.4 to 3.9) [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/120887.html" rel="external">"Toxoplasmosis: Acute systemic disease", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H1378977176"><span class="h2">Risk of reactivation</span><span class="headingEndMark"> — </span>The probability of developing reactivated toxoplasmosis is as high as 30 percent among patients with a CD4 count &lt;100 cells/microL who are toxoplasma seropositive and are not receiving effective prophylaxis or antiretroviral therapy [<a href="#rid8">8-11</a>]. The most common site of reactivation is the central nervous system (CNS).</p><p>Prior to the introduction of effective antiretroviral therapy (ART), the incidence of toxoplasmic encephalitis (TE) in patients with AIDS reflected the seropositivity rates in this population [<a href="#rid12">12</a>]. However, effective ART has decreased the incidence of TE. As an example, among patients with HIV in the United States, the annual number of toxoplasmosis-related hospitalizations peaked at more than 10,000 in 1995, dropped sharply to 3643 in 2001, and then decreased to 2985 in 2008 [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/3724.html" rel="external">"The natural history and clinical features of HIV infection in adults and adolescents"</a>.)</p><p>Extracerebral toxoplasmosis is much less common than CNS disease. This was illustrated in a series of 1699 patients with HIV from France, of whom 116 had confirmed, probable, or possible toxoplasmosis [<a href="#rid14">14</a>]. Cerebral toxoplasmosis was identified in 89 percent of patients, with pulmonary, ocular, and disseminated infection responsible for 6, 3.5, and 1.7 percent of cases, respectively. </p><p>The most prominent risk factor for the development of extracerebral toxoplasmosis is advanced immunosuppression (eg, CD4 count &lt;100 cells/microL) [<a href="#rid14">14,15</a>]. In addition, concurrent CNS disease is often seen. In one series of 199 patients with extracerebral toxoplasmosis, CNS disease was also present in 41 percent of patients [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Reactivation of toxoplasmosis most frequently presents with signs and symptoms of central nervous system disease in patients with HIV and a CD4 count &lt;100 cells/microL. (See <a class="local">'Toxoplasmic encephalitis'</a> below.)</p><p>Extracerebral disease can also occur, and may be present at more than one site [<a href="#rid15">15</a>]. (See <a class="local">'Extracerebral toxoplasmosis'</a> below.)</p><p>There are no routine laboratory findings that are specific for toxoplasmosis. However, the LDH can be markedly increased in patients with disseminated toxoplasmosis and pulmonary disease [<a href="#rid16">16,17</a>]. Evaluation of cerebrospinal fluid (CSF) typically reveals a mild mononuclear pleocytosis and an elevated protein.</p><p class="headingAnchor" id="H7"><span class="h2">Toxoplasmic encephalitis</span><span class="headingEndMark"> — </span>Patients with toxoplasmic encephalitis typically present with headache and/or other neurologic symptoms. Fever is usually, but not reliably, present. As an example, in a retrospective review of 115 cases, 55, 52, and 47 percent had headache, confusion, and fever, respectively [<a href="#rid1">1</a>]. Focal neurologic deficits or seizures are also common. Mental status changes range from dull affect to stupor and coma and can result from global encephalitis and/or increased intracranial pressure. </p><p class="headingAnchor" id="H8"><span class="h2">Extracerebral toxoplasmosis</span><span class="headingEndMark"> — </span>Pulmonary and ocular findings are the most common extracerebral manifestations, although disseminated disease can also occur.</p><p class="headingAnchor" id="H9"><span class="h3">Pneumonitis</span><span class="headingEndMark"> — </span>Toxoplasmic pneumonitis presents with fever, dyspnea, and a non-productive cough [<a href="#rid18">18</a>]. Chest radiographs typically have reticulonodular infiltrates. The clinical picture may be indistinguishable from <em>Pneumocystis jirovecii</em> (formerly <em>carinii</em>) pneumonia (ie, PCP). (See  <a class="medical medical_review" href="/z/d/html/3714.html" rel="external">"Toxoplasma pneumonia and other parasitic pulmonary infections in patients with HIV"</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">Chorioretinitis</span><span class="headingEndMark"> — </span>Patients with toxoplasmic chorioretinitis (a posterior uveitis) usually present with eye pain and decreased visual acuity. Toxoplasmic chorioretinitis appears as raised, yellow-white cottony lesions in a non-vascular distribution (unlike the perivascular exudates of CMV retinitis). Chorioretinitis due to <em>T. gondii</em> can rarely mimic acute retinal necrosis [<a href="#rid19">19</a>]. </p><p class="headingAnchor" id="H11"><span class="h3">Other manifestations</span><span class="headingEndMark"> — </span>Toxoplasmosis can rarely present at a variety of other sites, including the gastrointestinal tract, liver, musculoskeletal system, heart, bone marrow, bladder, spinal cord, and testes [<a href="#rid15">15,20,21</a>]. Disseminated disease presenting with septic shock has also been reported and can result from reactivation disease or primary infection [<a href="#rid22">22</a>]. In some cases, involvement of the organ system may only be appreciated on autopsy [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H12"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H13"><span class="h2">Approach to diagnosis</span><span class="headingEndMark"> — </span>In the majority of patients, therapy is initiated after making a presumptive, rather than definitive, diagnosis of toxoplasmic encephalitis (TE). (See <a class="local">'Treatment'</a> below.)</p><p>A definitive diagnosis of TE requires a compatible clinical syndrome (eg, headache, neurological symptoms, fever), identification of one or more mass lesions by brain imaging, and detection of the organism in a biopsy specimen [<a href="#rid5">5</a>]. However, for most patients presenting with central nervous system (CNS) disease, a presumptive diagnosis of TE is made in order to avoid a brain biopsy, given the associated morbidity and mortality of the procedure. (See  <a class="medical medical_review" href="/z/d/html/3718.html" rel="external">"Approach to the patient with HIV and central nervous system lesions", section on 'Brain biopsy'</a>.)</p><p>A presumptive diagnosis can be made if the patient has a CD4 count &lt;100 cells/microL, has not been receiving effective prophylaxis to prevent toxoplasmosis (see <a class="local">'Primary prophylaxis'</a> below), and has all of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A compatible clinical syndrome (see <a class="local">'Toxoplasmic encephalitis'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A positive <em>T. gondii</em> IgG antibody (see <a class="local">'Serology'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Brain imaging (preferably magnetic resonance imaging) that demonstrates a typical radiographic appearance (eg, multiple ring-enhancing lesions) (see <a class="local">'Imaging'</a> below)</p><p></p><p>If these criteria are present, there is a 90 percent probability that the diagnosis is TE [<a href="#rid4">4,24</a>]. For patients who can safely undergo lumbar puncture, analysis of cerebrospinal fluid (CSF) should also be performed to evaluate for evidence of <em>T. gondii</em>, as well as other infectious and non-infectious causes of CNS lesions. If toxoplasmosis is identified using polymerase chain reaction (PCR), the diagnosis of TE is even more likely (see <a class="local">'Polymerase chain reaction'</a> below). A detailed discussion on the evaluation of individuals with HIV and CNS lesions is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3718.html" rel="external">"Approach to the patient with HIV and central nervous system lesions"</a>.)</p><p>An alternative diagnosis becomes more likely if all of the above criteria are <strong>not</strong> met, CSF evaluation reveals an alternative diagnosis, <strong>or</strong> the patient has not responded to initial therapy (see <a class="local">'Response to therapy'</a> below). In such cases, other diagnostic tests and/or brain biopsy should be performed. As an example, if a solitary CNS lesion is detected, even if toxoplasma serology is positive, then evaluation for CNS lymphoma should be performed [<a href="#rid25">25</a>]. Which tests to order depends upon the clinical presentation. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>Establishing a diagnosis of extracerebral toxoplasmosis also depends upon the clinical presentation. For those with pulmonary disease, demonstration of tachyzoites in tissue or fluid (eg, bronchoalveolar lavage) is usually required (see  <a class="medical medical_review" href="/z/d/html/3721.html" rel="external">"Evaluation of pulmonary symptoms in persons with HIV"</a>). For those with ocular manifestations, the diagnosis is made based upon clinical findings consistent with toxoplasmosis. (See <a class="local">'Chorioretinitis'</a> above.)</p><p class="headingAnchor" id="H14"><span class="h2">Serology</span><span class="headingEndMark"> — </span>The vast majority of patients with TE are seropositive for anti-toxoplasma IgG antibodies [<a href="#rid26">26</a>]. The absence of antibodies to toxoplasma makes the diagnosis less likely, but does not completely exclude the possibility of TE [<a href="#rid5">5</a>]. Anti-toxoplasma IgM antibodies are usually absent and quantitative IgG antibody titers are not helpful. </p><p class="headingAnchor" id="H15"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>Magnetic resonance imaging (MRI), if available, is the imaging modality of choice for evaluating patients with possible TE. Most AIDS patients with TE have multiple ring-enhancing brain lesions, often associated with edema. In a report of 45 patients with TE who underwent computed tomography (CT) or MRI, for example, 31 (69 percent) had multiple lesions and 14 had single lesions [<a href="#rid27">27</a>]. There is a predilection for involvement of the basal ganglia [<a href="#rid20">20</a>]. </p><p>MRI is more sensitive than CT for identifying the lesions associated with TE [<a href="#rid28">28,29</a>]. This was illustrated in a prospective study of 50 patients with AIDS and neurologic symptoms that compared MRI and CT for the evaluation of TE [<a href="#rid28">28</a>]. The MRI influenced the diagnosis and treatment of 20 patients (40 percent) whose lesions were not characterized by CT. However, neither CT nor MRI can adequately distinguish toxoplasmosis from other CNS lesions (eg, CNS lymphoma, cryptococcoma). A discussion on the differential diagnosis of patients with HIV presenting with CNS lesions is found elsewhere. (See <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/z/d/html/3718.html" rel="external">"Approach to the patient with HIV and central nervous system lesions"</a>.)</p><p class="headingAnchor" id="H45189708"><span class="h2">Occasionally performed tests</span></p><p class="headingAnchor" id="H17"><span class="h3">Nuclear imaging</span><span class="headingEndMark"> — </span>Thallium single photon emission computed tomography (SPECT) and positron emission tomography (PET) can be useful in distinguishing CNS lymphoma from TE or other infections. Lymphoma has greater thallium uptake on SPECT, and greater glucose and methionine metabolism on PET, compared with TE or other infections [<a href="#rid30">30-32</a>]. This imaging modality is particularly useful for patients with solitary lesions who are poor candidates for brain biopsy [<a href="#rid33">33,34</a>]. </p><p class="headingAnchor" id="H824493468"><span class="h3">Visualization of the organism</span><span class="headingEndMark"> — </span>A definitive diagnosis of TE is made by visualization of organisms on brain tissue obtained by open or stereotactic brain biopsy. Organisms are typically demonstrated on hematoxylin and eosin stains; however, immunoperoxidase staining may increase the diagnostic sensitivity [<a href="#rid35">35</a>]. Tachyzoites can also been seen in fluid specimens including cytocentrifuged cerebrospinal fluid samples and bronchoalveolar lavage. The sensitivity of brain biopsy is as high as 93 percent [<a href="#rid36">36</a>]. </p><p class="headingAnchor" id="H878459301"><span class="h3">Polymerase chain reaction</span><span class="headingEndMark"> — </span>Detection of <em>T. gondii</em> by PCR in cerebrospinal fluid has demonstrated high specificity (96 to 100 percent), but variable sensitivity (50 to 98 percent), depending upon the primers used [<a href="#rid37">37-39</a>]. Treatment also affects diagnostic sensitivity. Thus, a positive PCR result establishes the diagnosis of TE, but a negative one does not rule it out.</p><p class="headingAnchor" id="H20"><span class="h1">DIFFERENTIAL DIAGNOSIS</span></p><p class="headingAnchor" id="H382302669"><span class="h2">Central nervous system disease</span><span class="headingEndMark"> — </span>The differential diagnosis of toxoplasmic encephalitis (TE) includes central nervous system (CNS) lymphoma, mycobacterial infection, cryptococcosis, bacterial abscess, and uncommonly, progressive multifocal leukoencephalopathy. Testing of cerebrospinal fluid for pathogens associated with these conditions (eg, Epstein-Barr virus [EBV], JC virus, <em>Mycobacterium tuberculosis</em>, <em>Cryptococcus neoformans</em>) can be used to help identify these alternative causes of infection [<a href="#rid36">36</a>]. A detailed discussion on the evaluation of patients with HIV and central nervous system lesions is found elsewhere  (<a class="graphic graphic_algorithm graphicRef50593" href="/z/d/graphic/50593.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/3718.html" rel="external">"Approach to the patient with HIV and central nervous system lesions"</a>.) </p><p><strong>Extracerebral disease</strong> — For patients with extracerebral toxoplasmosis, the differential depends upon the organ system involved. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>The differential diagnosis of pulmonary symptoms in individuals with HIV is broad and can include bacterial, viral, mycobacterial, and fungal pathogens. A discussion on the differential diagnosis of individuals with HIV and pulmonary symptoms and the approach to diagnosis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3704.html" rel="external">"Epidemiology, clinical presentation, and diagnosis of Pneumocystis pulmonary infection in patients with HIV", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/3721.html" rel="external">"Evaluation of pulmonary symptoms in persons with HIV"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The ocular manifestations of toxoplasmosis can be confused with other infections in HIV, such as retinitis resulting from cytomegalovirus and acute retinal necrosis due to varicella-zoster virus. (See  <a class="medical medical_review" href="/z/d/html/3746.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/8327.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes zoster", section on 'Acute retinal necrosis'</a>.)</p><p></p><p class="headingAnchor" id="H21"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The treatment of toxoplasmosis in patients with HIV includes antimicrobial therapy directed against <em>T. gondii</em> as well as antiretroviral therapy (ART) for immune recovery. Extracerebral toxoplasmosis is treated with the same regimens as toxoplasmic encephalitis (TE), although the response may not be as favorable [<a href="#rid15">15</a>]. </p><p class="headingAnchor" id="H1806040243"><span class="h2">Antimicrobial therapy</span></p><p class="headingAnchor" id="H202076538"><span class="h3">Initial therapy</span><span class="headingEndMark"> — </span>Antimicrobial therapy targeted against <em>T. gondii</em> involves an initial phase to treat the acute symptoms. For patients who respond to treatment, the duration is typically six weeks. Following that, patients should be transitioned to maintenance therapy to reduce the risk of recurrence. (See <a class="local">'Maintenance therapy'</a> below.)</p><p class="headingAnchor" id="H202076881"><span class="h4">Preferred regimens</span><span class="headingEndMark"> — </span>For patients with toxoplasmosis we suggest <strong>either</strong> of the following regimens:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9960" href="/z/d/drug information/9960.html" rel="external">Sulfadiazine</a><strong> plus </strong><a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a> – This drug regimen is only given orally and should be dosed as follows [<a href="#rid5">5,27,40-42</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9960" href="/z/d/drug information/9960.html" rel="external">Sulfadiazine</a> (1000 mg orally four times daily among patients &lt;60 kg or 1500 mg four times daily among patients ≥60 kg). If there are concerns about nonadherence, 2000 mg of sulfadiazine can be administered twice daily; one study documented equivalent pharmacokinetic parameters of this dosing schedule compared with 1000 mg given four times a day [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">Pyrimethamine</a> (200 mg loading dose followed by 50 mg daily among patients &lt;60 kg <strong>or</strong> 75 mg daily among patients ≥60 kg).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">Leucovorin</a> (10 to 25 mg daily) should also be administered to prevent pyrimethamine-induced hematologic toxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a><strong> (TMP-SMX)</strong> – 5 mg/kg <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a> and 25 mg/kg sulfamethoxazole given orally or intravenously twice daily. </p><p></p><p>Patients receiving either of these regimens do not require additional prophylaxis against <em>P. jirovecii</em> infections (ie, PCP). (See  <a class="medical medical_review" href="/z/d/html/3747.html" rel="external">"Overview of prevention of opportunistic infections in patients with HIV"</a>.)</p><p>Traditionally, <a class="drug drug_general" data-topicid="9960" href="/z/d/drug information/9960.html" rel="external">sulfadiazine</a> plus <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a> was the preferred regimen since early studies found it to be more effective compared with alternative choices, such as <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> plus pyrimethamine [<a href="#rid41">41</a>], and there was most experience with this regimen. However, TMP-SMX is frequently used in resource-limited settings given the low cost [<a href="#rid44">44</a>] and has been increasingly used in resource-rich settings since access to pyrimethamine has been limited [<a href="#rid45">45</a>]. Available data suggest TMP-SMX is as effective as sulfadiazine plus pyrimethamine, and it may be better tolerated [<a href="#rid46">46-48</a>]. In a systematic review that compared sulfadiazine plus pyrimethamine with several regimens, including TMP-SMX, these two regimens had similar rates of partial or complete clinical response as well as a similar risk of adverse events such as skin rash [<a href="#rid48">48</a>]. </p><p class="headingAnchor" id="H22"><span class="h4">Patients with sulfonamide allergy</span><span class="headingEndMark"> — </span>There are several treatment options for patients with a sulfonamide allergy. These include: </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">Clindamycin</a><strong> plus </strong><a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a> – For patients who cannot take sulfonamides, we typically prefer clindamycin (600 mg intravenously or orally four times a day) <strong>plus</strong> oral pyrimethamine (200 mg loading dose followed by 50 mg daily among patients &lt;60 kg <strong>or</strong> 75 mg daily among patients ≥60 kg) <strong>plus</strong> oral <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> (10 to 25 mg daily). Patients who receive clindamycin plus pyrimethamine must receive an additional agent for prevention of <em>Pneumocystis</em> pneumonia. (See  <a class="medical medical_review" href="/z/d/html/3709.html" rel="external">"Treatment and prevention of Pneumocystis infection in patients with HIV", section on 'Patients with a sulfa allergy'</a>.) </p><p></p><p class="bulletIndent1">In a study of 49 patients treated for TE with <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a> plus <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>, 35 (71 percent) responded overall with the vast majority demonstrating ≥50 percent improvement in their baseline abnormalities by day 14 of therapy [<a href="#rid27">27</a>]. However, people receiving this regimen may be more likely to relapse compared to those receiving <a class="drug drug_general" data-topicid="9960" href="/z/d/drug information/9960.html" rel="external">sulfadiazine</a> plus pyrimethamine [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sulfa desensitization</strong> – If <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a> is not available, sulfa desensitization should be attempted in those without a history of a severe reaction (eg, Stevens Johnson Syndrome). <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">Atovaquone</a> (1500 mg orally twice daily) should be administered until the patient is able to tolerate a therapeutic dose of TMP-SMX [<a href="#rid5">5</a>]. Additional information on sulfonamide allergy and TMP-SMX desensitization are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2080.html" rel="external">"Sulfonamide allergy in HIV-uninfected patients", section on 'Types of hypersensitivity reactions'</a> and  <a class="medical medical_review" href="/z/d/html/3709.html" rel="external">"Treatment and prevention of Pneumocystis infection in patients with HIV", section on 'Desensitization for patients with a sulfa allergy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">Atovaquone</a><strong> containing regimen</strong> – Several different atovaquone containing regimens can be used for treatment of toxoplasmosis. These include [<a href="#rid49">49-52</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">Atovaquone</a> (1500 mg orally twice daily) <strong>plus </strong><a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a> (200 mg loading dose followed by 50 mg daily among patients &lt;60 kg <strong>or</strong> 75 mg daily among patients ≥60 kg) <strong>plus</strong> <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> (10 to 25 mg orally once daily).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">Atovaquone</a> (1500 mg orally twice daily) <strong>plus</strong> <a class="drug drug_general" data-topicid="9960" href="/z/d/drug information/9960.html" rel="external">sulfadiazine</a> (1000 mg orally four times daily among patients &lt;60 kg or 1500 mg orally four times daily among patients ≥60 kg).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">Atovaquone</a> (1500 mg orally twice daily).</p><p></p><p class="bulletIndent1">Although <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">atovaquone</a> is usually well tolerated, we prefer one of the other approaches for treatment of toxoplasmosis since there is variable absorption of atovaquone. </p><p></p><p class="headingAnchor" id="H24"><span class="h4">Adjunctive therapies</span><span class="headingEndMark"> — </span>There are several therapies that can be administered to help manage the complications of TE. These include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Corticosteroids</strong> – Adjunctive corticosteroids should only be used for patients with mass effect related to focal brain lesions or edema (eg, individuals with radiographic evidence of midline shift). <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">Dexamethasone</a> (4 mg every six hours) is usually chosen and is generally tapered over several days.</p><p></p><p class="bulletIndent1">When corticosteroids are used, it may be difficult to assess response to therapy since corticosteroids can result in a rapid improvement in symptoms. Radiographic assessments may also be affected since the corticosteroids will reduce the intensity of ring-enhancement and the amount of surrounding edema. Patients should also be carefully monitored for the development of other opportunistic infections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anticonvulsants</strong> – Anticonvulsants should be administered to patients who present with seizures. They should not be given routinely for prophylaxis to all patients with a presumed diagnosis of TE [<a href="#rid5">5</a>]. Careful attention needs to be paid to any potential drug interactions.</p><p></p><p class="headingAnchor" id="H971178678"><span class="h3">Patient monitoring</span><span class="headingEndMark"> — </span>The monitoring of patients with TE includes assessment for adverse drug reactions and clinical improvement, as well as serial brain imaging. There is no value of following IgG toxoplasma antibody titers. (See <a class="local">'Serology'</a> above.)</p><p class="headingAnchor" id="H88277034"><span class="h4">Adverse reactions</span><span class="headingEndMark"> — </span>Common side effects of <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a> include rash, nausea, and bone marrow suppression. Higher doses of <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a>, (50 mg daily or twice daily), can be administered for management of hematologic abnormalities [<a href="#rid5">5</a>]. <a class="drug drug_general" data-topicid="9960" href="/z/d/drug information/9960.html" rel="external">Sulfadiazine</a> can lead to rash, fever, leukopenia, hepatitis, nausea, vomiting, diarrhea, and crystalluria (leading to renal insufficiency). <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">Clindamycin</a> can also lead to fever, rash, and nausea; its use is also associated with diarrhea related to production of <em>Clostridioides</em> <em>difficile </em>toxin.</p><p class="headingAnchor" id="H26"><span class="h4">Response to therapy</span><span class="headingEndMark"> — </span>For patients with TE, we assess for clinical improvement during the first two weeks of therapy. Clinical improvement usually precedes radiographic improvement. Thus, careful daily neurologic examinations are more important than radiographic studies in assessing the initial response to therapy. </p><p>We perform neuroimaging after two to three weeks of treatment, or sooner if the patient has not demonstrated clinical improvement within the first week or has shown any worsening. Lack of clinical and/or radiographic improvement within 10 to 14 days of starting empiric therapy for TE should raise the possibility of an alternative diagnosis. Brain biopsy should be considered in such patients. (See  <a class="medical medical_review" href="/z/d/html/3718.html" rel="external">"Approach to the patient with HIV and central nervous system lesions"</a>.)</p><p>Approximately 75 to 80 percent of patients treated for TE demonstrate clinical and radiologic improvement [<a href="#rid27">27,51</a>]. As an example, in a study of 49 patients treated for TE with <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a> plus <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>, 35 (71 percent) responded overall with the vast majority demonstrating ≥50 percent improvement in their baseline abnormalities by day 14 of therapy [<a href="#rid27">27</a>]. However, the literature dealing with response to therapy is hampered by presumptive diagnoses, cross-over treatments, and discontinuation for toxicity, rather than lack of clinical response.</p><p class="headingAnchor" id="H28"><span class="h3">Special considerations during pregnancy</span><span class="headingEndMark"> — </span>Pregnant women who acquire toxoplasmosis during pregnancy should be managed in conjunction with a maternal-fetal medicine specialist. A detailed discussion on the diagnosis and management of pregnant women with primary toxoplasmosis infection is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy"</a>.)</p><p>Patients with HIV who become pregnant are typically managed by a maternal-fetal medicine specialist in conjunction with an infectious disease specialist. The approach to treatment of such women who develop TE should be the same as in the nonpregnant adult [<a href="#rid5">5</a>]. Although <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a> has been associated with birth defects in animals, limited human data have not suggested an increased risk of teratogenicity, and guidelines endorse its use in pregnant women after the first trimester [<a href="#rid5">5,53</a>]. In addition, ultrasound examination of the fetus should be performed to assess for evidence of congenital infection (eg, hydrocephalus, cerebral calcifications, and growth restriction) [<a href="#rid5">5</a>]. There have been case reports of <em>T. gondii</em> transmission from women with HIV and significant immunosuppression and symptomatic reactivation disease to their fetus [<a href="#rid54">54</a>]. Congenital transmission of <em>T. gondii</em> among asymptomatic women with HIV who are not immunosuppressed has not been reported [<a href="#rid55">55-57</a>]. </p><p class="headingAnchor" id="H202076667"><span class="h3">Maintenance therapy</span><span class="headingEndMark"> — </span>We transition most patients to maintenance therapy after six weeks of treatment with the initial regimen. This includes both patients with TE and extracerebral disease. (See <a class="local">'Initial therapy'</a> above.)</p><p>The goal of maintenance therapy (also referred to as secondary prophylaxis) is to prevent relapse of infection. Antimicrobial therapy is only active against the tachyzoite form (not the cyst form); thus, relapse of infection may occur after initial therapy unless the patient has immunologic recovery [<a href="#rid4">4</a>]. </p><p>For patients with TE, we perform neuroimaging prior to this transition to establish a new baseline. This information can be useful if there is concern for relapse or an immune reconstitution inflammatory syndrome (IRIS). (See  <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome"</a>.)</p><p class="headingAnchor" id="H202076869"><span class="h4">Regimens for maintenance therapy</span><span class="headingEndMark"> — </span>We suggest one of the following regimens for maintenance therapy: </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9960" href="/z/d/drug information/9960.html" rel="external">Sulfadiazine</a> (2000 to 4000 mg daily in two to four divided doses) with <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a> (25 to 50 mg daily) and <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> (10 to 25 mg daily) [<a href="#rid5">5</a>]. We favor twice-daily dosing of sulfadiazine for patient convenience, and typically administer 1000 mg twice daily for individuals &lt;60 kg and 1500 mg twice daily for individuals ≥60 kg. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>TMP-SMX (one double strength tablet twice daily) [<a href="#rid46">46,58</a>].</p><p></p><p>In one study that was conducted before the introduction of effective ART, the relapse rate in patients receiving <a class="drug drug_general" data-topicid="9960" href="/z/d/drug information/9960.html" rel="external">sulfadiazine</a> plus <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a> maintenance therapy was 11 percent [<a href="#rid41">41</a>]. In a subsequent study of 17 patients who were receiving protease-inhibitor based ART, only one relapse occurred when TMP-SMX was used for maintenance therapy [<a href="#rid58">58</a>]. </p><p>Alternative oral maintenance regimens include [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">Clindamycin</a> (600 mg every eight hours) plus <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a> (25 to 50 mg daily) plus <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> (10 to 25 mg daily) [<a href="#rid5">5,41</a>]. If this regimen is used, an additional agent should be administered to prevent <em>Pneumocystis</em> pneumonia. (See  <a class="medical medical_review" href="/z/d/html/3709.html" rel="external">"Treatment and prevention of Pneumocystis infection in patients with HIV", section on 'Regimens for prophylaxis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">Atovaquone</a> (750 to 1500 mg twice daily) with <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a> (25 mg daily) plus <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> (10 mg daily) [<a href="#rid5">5,50,59</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">Atovaquone</a> (750 to 1500 mg twice daily) with <a class="drug drug_general" data-topicid="9960" href="/z/d/drug information/9960.html" rel="external">sulfadiazine</a> (2000 to 4000 mg daily in two to four divided doses). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">Atovaquone</a> monotherapy (750 to 1500 mg twice daily) can be administered to patients who cannot tolerate <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a>, but the one-year relapse rate may be higher (26 percent) [<a href="#rid59">59</a>].</p><p></p><p class="headingAnchor" id="H202076360"><span class="h4">Discontinuing maintenance therapy</span><span class="headingEndMark"> — </span>Chronic maintenance therapy (ie, secondary prophylaxis) for TE can be discontinued in asymptomatic patients who have completed initial therapy if they are receiving ART, have a suppressed HIV viral load, and have maintained a CD4 count &gt;200 cells/microL for at least six months [<a href="#rid5">5</a>]. Various studies show that immune responses against <em>T. gondii</em> are restored in such patients [<a href="#rid60">60,61</a>]. </p><p>We do <strong>not</strong> use neuroimaging to guide our decision about when to stop secondary prophylaxis. We repeat neuroimaging after induction therapy to get a post-treatment baseline and monitor patients clinically for relapse. However, some experts obtain magnetic resonance imaging of the brain to decide if it is safe to stop maintenance therapy, and they base their decision upon the presence of residual disease.</p><p>Patients who stop maintenance therapy should be educated to seek medical attention for recurrent symptoms since relapses have been reported [<a href="#rid60">60,62-65</a>]. Maintenance therapy should be reinitiated if the CD4 cell count declines to ≤200 cells/microL. A discussion of when to initiate ART is found below. (See <a class="local">'Antiretroviral therapy'</a> below.)</p><p class="headingAnchor" id="H1417437120"><span class="h2">Antiretroviral therapy</span><span class="headingEndMark"> — </span>Most patients with toxoplasmosis are not receiving antiretroviral therapy (ART) at the time of diagnosis. We initiate ART within two weeks of starting treatment for toxoplasmosis, typically as soon as it is clear that the patient is tolerating toxoplasmosis therapy. </p><p>Although there are no definitive studies on the optimal time to initiate ART in patients with toxoplasmosis, the benefits of early ART (eg, reduced disease progression and death) have been demonstrated in patients with a variety of opportunistic infections, including some with toxoplasmosis [<a href="#rid5">5,66</a>]. </p><p>Detailed discussions of ART are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3777.html" rel="external">"When to initiate antiretroviral therapy in persons with HIV", section on 'Patients with opportunistic infections'</a> and  <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"</a> and  <a class="medical medical_review" href="/z/d/html/129782.html" rel="external">"Selecting antiretroviral regimens for treatment-naive persons with HIV-1: Patients with comorbid conditions"</a>.)</p><p class="headingAnchor" id="H10923597"><span class="h1">TOXOPLASMOSIS AND IMMUNE RECONSTITUTION SYNDROME (IRIS)</span><span class="headingEndMark"> — </span>The term "immune reconstitution inflammatory syndrome" (IRIS) describes a collection of inflammatory disorders associated with paradoxical worsening of pre-existing infectious processes following the initiation of effective antiretroviral therapy (ART) in individuals with HIV [<a href="#rid67">67-72</a>]. (See  <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome"</a>.)</p><p>IRIS can complicate central nervous system (CNS) infections, as has been well described for mycobacteria and cryptococcal infections. However, fewer cases of IRIS related to CNS toxoplasmosis have been reported [<a href="#rid73">73,74</a>]. IRIS in association with toxoplasmosis can lead to a paradoxical worsening of symptoms with worsening edema surrounding brain lesions as CD4 cell counts rapidly improve [<a href="#rid74">74</a>]. Management includes continuing treatment for toxoplasmic encephalitis (TE) and antiretroviral treatment for HIV, and increasing the dose of steroids, as needed, to control symptoms. If the diagnosis of IRIS is unclear, a biopsy may be needed to rule out an alternative process, such as lymphoma [<a href="#rid74">74</a>].</p><p>In patients without a prior diagnosis of TE, IRIS can present as an "unmasking" of an infection that previously existed, but was not diagnosed until the onset of immune recovery. In one case series of 65 patients with TE, three were diagnosed with CNS disease only after the initiation of ART [<a href="#rid75">75</a>]. In such patients, symptoms occurred at a median time of 41 days after starting antiretroviral therapy and at a median CD4 count of 222 cells/microL.</p><p class="headingAnchor" id="H29"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>For patients with HIV, the risk of developing toxoplasmosis can be reduced by avoiding exposure to the pathogen or by using prophylactic antibiotics to decrease the risk of reactivation. </p><p class="headingAnchor" id="H1467631667"><span class="h2">Assessing for prior exposure</span><span class="headingEndMark"> — </span>All patients with HIV should be tested for prior exposure to <em>T. gondii</em> by measuring anti-toxoplasma IgG, ideally when first diagnosed with HIV [<a href="#rid76">76</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>For patients <strong>without</strong> evidence of prior infection with toxoplasmosis, initial infection can be prevented by taking certain precautions. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/120887.html" rel="external">"Toxoplasmosis: Acute systemic disease", section on 'Prevention'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For individuals <strong>with</strong> evidence of prior toxoplasmosis (ie, those with a positive serology), antimicrobial therapy can decrease the risk of developing reactivation disease. This is referred to as primary prophylaxis and is described below. (See <a class="local">'Primary prophylaxis'</a> below.)</p><p></p><p class="headingAnchor" id="H30"><span class="h2">Primary prophylaxis</span><span class="headingEndMark"> — </span>Patients with HIV and a CD4 count &lt;100 cells/microL should receive antimicrobial prophylaxis to prevent toxoplasmosis if they are <em>T. gondii</em> IgG positive. The probability of developing reactivated toxoplasmosis is as high as 30 percent among patients with a CD4 count &lt;100 cells/microL who are toxoplasma seropositive and are not receiving effective prophylaxis or antiretroviral therapy [<a href="#rid8">8-11</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>Our preferred regimen is <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX) one double strength (DS) tablet (800 mg/160 mg) per day. For patients unable to tolerate this dose, TMP-SMX can be given as one DS tablet three times per week or one single strength tablet (400 mg/80 mg) daily. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the patient cannot take TMP-SMX, one of the following oral regimens can be used [<a href="#rid5">5</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">Dapsone</a> (50 mg once daily) plus <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a> (50 mg per week) plus <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> (25 mg per week) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">Dapsone</a> (200 mg per week) plus <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a> (75 mg per week) plus <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> (25 mg per week) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">Atovaquone</a> (1500 mg once daily) with or without <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a> (25 mg once daily); if pyrimethamine is given, <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> (10 mg daily) should also be used</p><p></p><p>Monotherapy with <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>, <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a>, <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>, or <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> is <strong>not</strong> recommended.</p><p>Most data on the efficacy of primary prophylaxis for toxoplasmosis come from retrospective analyses of trials evaluating antimicrobial treatment to prevent <em>Pneumocystis</em> infection [<a href="#rid77">77-80</a>]. In patients with AIDS, the risk of developing toxoplasmic encephalitis (TE) in those who are using primary prophylaxis is 0 to 2.4 percent for TMP-SMX and 0 to 11 percent for dapsone-pyrimethamine [<a href="#rid81">81</a>]. <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">Atovaquone</a> for primary prophylaxis of toxoplasmosis has not been studied, and the recommendation for its use as an alternate agent for primary prophylaxis is based upon its efficacy in the treatment of TE. (See <a class="local">'Patients with sulfonamide allergy'</a> above.)</p><p>For pregnant women who have a CD4 cell count &lt;100 cells/microL, the benefit of prophylaxis must be weighed against the risk to the fetus. The specific risks depend upon the type of prophylaxis used. A discussion on the risk of TMP-SMX during pregnancy is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/13972.html" rel="external">"Prenatal evaluation of women with HIV in resource-rich settings", section on 'Chemoprophylaxis for opportunistic infections'</a>.)</p><p class="headingAnchor" id="H32"><span class="h2">Discontinuation of primary prophylaxis</span><span class="headingEndMark"> — </span>Patients receiving antiretroviral therapy can safely discontinue primary prophylaxis for toxoplasmosis if their HIV viral load is suppressed and their CD4 count is &gt;200 cells/microL for at least three months [<a href="#rid5">5,82,83</a>]. This is supported by a study of 199 patients who discontinued primary prophylaxis for toxoplasmosis after having a sustained increase in their CD4 count (&gt;200 cells/microL) for &gt;12 weeks while receiving antiretroviral therapy (ART) [<a href="#rid82">82</a>]. None of the patients developed toxoplasmic encephalitis during a follow-up of 272 person-years. Prophylaxis should be reinstated if the CD4 count drops to &lt;100 to 200 cells/microL [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H2244368820"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111612.html" rel="external">"Society guideline links: Opportunistic infections in adults with HIV"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/113063.html" rel="external">"Society guideline links: Toxoplasmosis"</a>.)</p><p class="headingAnchor" id="H33"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – The probability of developing reactivated toxoplasmosis is as high as 30 percent among AIDS patients with a CD4 count &lt;100 cells/microL who are toxoplasma seropositive and are not receiving effective prophylaxis or antiretroviral therapy. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Reactivation of toxoplasmosis most frequently presents with signs and symptoms of central nervous system disease in patients with HIV and a CD4 count &lt;100 cells/microL. Extracerebral disease can also occur and may be present at more than one site. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – In the majority of patients, therapy is initiated after making a presumptive, rather than definitive, diagnosis of toxoplasmic encephalitis (TE). (See <a class="local">'Approach to diagnosis'</a> above.)</p><p></p><p class="bulletIndent1">A presumptive diagnosis of TE can be made if the patient has a CD4 count &lt;100 cells/microL, has not been receiving effective prophylaxis for toxoplasma, and has all of the following (see <a class="local">'Approach to diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A compatible clinical syndrome (see <a class="local">'Toxoplasmic encephalitis'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A positive <em>T. gondii</em> IgG antibody (see <a class="local">'Serology'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Brain imaging (preferably magnetic resonance imaging) that demonstrates a typical radiographic appearance (eg, multiple ring-enhancing lesions) (see <a class="local">'Imaging'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of TE includes central nervous system (CNS) lymphoma, tuberculoma, cryptococcoma, bacterial abscess, and uncommonly, progressive multifocal leukoencephalopathy. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – The treatment of toxoplasmosis in patients with HIV includes antimicrobial therapy directed against <em>T. gondii</em>, as well as antiretroviral therapy (ART) for immune recovery. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial therapy</strong> – For most patients, we suggest an initial regimen containing <a class="drug drug_general" data-topicid="9960" href="/z/d/drug information/9960.html" rel="external">sulfadiazine</a> plus <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a> or <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). While data are limited, these regimens appear to be similarly effective and many people use TMP-SMX as it is more universally available. (See <a class="local">'Preferred regimens'</a> above.)</p><p></p><p class="bulletIndent2">If the patient cannot tolerate a sulfonamide, alternative regimens include <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a> plus <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> or an atovaquone-containing regimen. (See <a class="local">'Patients with sulfonamide allergy'</a> above.)</p><p></p><p class="bulletIndent2">For patients who respond to treatment, the duration of initial therapy is typically six weeks. (See <a class="local">'Initial therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Maintenance therapy</strong> – For patients who complete initial therapy, we suggest maintenance therapy (ie, secondary prophylaxis) with <a class="drug drug_general" data-topicid="9960" href="/z/d/drug information/9960.html" rel="external">sulfadiazine</a> plus <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a> or TMP-SMX (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Relapse of infection can occur after initial therapy unless the patient has immunologic recovery. (See <a class="local">'Regimens for maintenance therapy'</a> above.)</p><p></p><p class="bulletIndent2">Maintenance therapy can be discontinued in asymptomatic patients who are receiving ART, have a suppressed HIV viral load, and have maintained a CD4 count &gt;200 cells/microL for at least six months. (See <a class="local">'Discontinuing maintenance therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiretroviral therapy</strong> – Most patients with toxoplasmosis are not on ART at the time of diagnosis. We initiate ART within two weeks of starting treatment for toxoplasmosis, typically as soon as it is clear that the patient is tolerating toxoplasmosis therapy. (See <a class="local">'Antiretroviral therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary prevention</strong> – For patients with HIV without evidence of prior <em>T. gondii</em> infection (<em>T.gondii</em> IgG negative), the risk of developing toxoplasmosis can be reduced by avoiding exposure to the pathogen.</p><p></p><p class="bulletIndent1">By contrast, for those who are <em>T.gondii</em> IgG positive with a CD4 cell count &lt;100 cells/microL, we suggest prophylactic TMP-SMX (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Prophylactic therapy with TMP-SMX reduces the risk of reactivating latent <em>T. gondii</em>. Our preferred regimen is one double strength (DS) tablet (800 mg/160 mg) per day. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="headingAnchor" id="H2873258715"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Howard Heller, MD, MPH, who contributed to an earlier version of this topic review.</p><p>UpToDate also gratefully acknowledges John G Bartlett, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med 1992; 327:1643.</a></li><li><a class="nounderline abstract_t">San-Andrés FJ, Rubio R, Castilla J, et al. Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989-1997. Clin Infect Dis 2003; 36:1177.</a></li><li><a class="nounderline abstract_t">Renold C, Sugar A, Chave JP, et al. Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome. Medicine (Baltimore) 1992; 71:224.</a></li><li><a class="nounderline abstract_t">Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 1992; 15:211.</a></li><li class="breakAll">National Institutes of Health. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV: Toxoplasma gondii Encephalitis. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/toxoplasma-gondii-encephalitis?view=full (Accessed on March 22, 2021).</li><li><a class="nounderline abstract_t">Falusi O, French AL, Seaberg EC, et al. Prevalence and predictors of Toxoplasma seropositivity in women with and at risk for human immunodeficiency virus infection. Clin Infect Dis 2002; 35:1414.</a></li><li><a class="nounderline abstract_t">Wallace MR, Rossetti RJ, Olson PE. Cats and toxoplasmosis risk in HIV-infected adults. JAMA 1993; 269:76.</a></li><li><a class="nounderline abstract_t">Grant IH, Gold JW, Rosenblum M, et al. Toxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis in AIDS. AIDS 1990; 4:519.</a></li><li><a class="nounderline abstract_t">Blaser MJ, Cohn DL. Opportunistic infections in patients with AIDS: clues to the epidemiology of AIDS and the relative virulence of pathogens. Rev Infect Dis 1986; 8:21.</a></li><li><a class="nounderline abstract_t">Leport C, Chêne G, Morlat P, et al. Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Group. J Infect Dis 1996; 173:91.</a></li><li><a class="nounderline abstract_t">Abgrall S, Rabaud C, Costagliola D, Clinical Epidemiology Group of the French Hospital Database on HIV. Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. Clin Infect Dis 2001; 33:1747.</a></li><li><a class="nounderline abstract_t">Levy RM, Janssen RS, Bush TJ, Rosenblum ML. Neuroepidemiology of acquired immunodeficiency syndrome. J Acquir Immune Defic Syndr 1988; 1:31.</a></li><li><a class="nounderline abstract_t">Jones JL, Roberts JM. Toxoplasmosis hospitalizations in the United States, 2008, and trends, 1993-2008. Clin Infect Dis 2012; 54:e58.</a></li><li><a class="nounderline abstract_t">Belanger F, Derouin F, Grangeot-Keros L, Meyer L. Incidence and risk factors of toxoplasmosis in a cohort of human immunodeficiency virus-infected patients: 1988-1995. HEMOCO and SEROCO Study Groups. Clin Infect Dis 1999; 28:575.</a></li><li><a class="nounderline abstract_t">Rabaud C, May T, Amiel C, et al. Extracerebral toxoplasmosis in patients infected with HIV. A French National Survey. Medicine (Baltimore) 1994; 73:306.</a></li><li><a class="nounderline abstract_t">Pugin J, Vanhems P, Hirschel B, et al. Extreme elevations of serum lactic dehydrogenase differentiating pulmonary toxoplasmosis from Pneumocystis pneumonia. N Engl J Med 1992; 326:1226.</a></li><li><a class="nounderline abstract_t">Butt AA, Michaels S, Kissinger P. The association of serum lactate dehydrogenase level with selected opportunistic infections and HIV progression. Int J Infect Dis 2002; 6:178.</a></li><li><a class="nounderline abstract_t">Rabaud C, May T, Lucet JC, et al. Pulmonary toxoplasmosis in patients infected with human immunodeficiency virus: a French National Survey. Clin Infect Dis 1996; 23:1249.</a></li><li><a class="nounderline abstract_t">Moshfeghi DM, Dodds EM, Couto CA, et al. Diagnostic approaches to severe, atypical toxoplasmosis mimicking acute retinal necrosis. Ophthalmology 2004; 111:716.</a></li><li class="breakAll">Montoya JG, Remington JS. Toxoplasma gondii. In: Principles and Practice of Infectious Diseases, 5th Edition, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2000. p.2858.</li><li><a class="nounderline abstract_t">Vyas R, Ebright JR. Toxoplasmosis of the spinal cord in a patient with AIDS: case report and review. Clin Infect Dis 1996; 23:1061.</a></li><li><a class="nounderline abstract_t">Lucet JC, Bailly MP, Bedos JP, et al. Septic shock due to toxoplasmosis in patients infected with the human immunodeficiency virus. Chest 1993; 104:1054.</a></li><li><a class="nounderline abstract_t">Hofman P, Bernard E, Michiels JF, et al. Extracerebral toxoplasmosis in the acquired immunodeficiency syndrome (AIDS). Pathol Res Pract 1993; 189:894.</a></li><li><a class="nounderline abstract_t">Cohn JA, McMeeking A, Cohen W, et al. Evaluation of the policy of empiric treatment of suspected Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome. Am J Med 1989; 86:521.</a></li><li><a class="nounderline abstract_t">Andrews BT, Kenefick TP. Neurosurgical management of the acquired immunodeficiency syndrome. An update. West J Med 1993; 158:249.</a></li><li><a class="nounderline abstract_t">Luft BJ, Brooks RG, Conley FK, et al. Toxoplasmic encephalitis in patients with acquired immune deficiency syndrome. JAMA 1984; 252:913.</a></li><li><a class="nounderline abstract_t">Luft BJ, Hafner R, Korzun AH, et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. N Engl J Med 1993; 329:995.</a></li><li><a class="nounderline abstract_t">Levy RM, Mills CM, Posin JP, et al. The efficacy and clinical impact of brain imaging in neurologically symptomatic AIDS patients: a prospective CT/MRI study. J Acquir Immune Defic Syndr 1990; 3:461.</a></li><li><a class="nounderline abstract_t">Ciricillo SF, Rosenblum ML. Use of CT and MR imaging to distinguish intracranial lesions and to define the need for biopsy in AIDS patients. J Neurosurg 1990; 73:720.</a></li><li><a class="nounderline abstract_t">Miller RF, Hall-Craggs MA, Costa DC, et al. Magnetic resonance imaging, thallium-201 SPET scanning, and laboratory analyses for discrimination of cerebral lymphoma and toxoplasmosis in AIDS. Sex Transm Infect 1998; 74:258.</a></li><li><a class="nounderline abstract_t">Skiest DJ, Erdman W, Chang WE, et al. SPECT thallium-201 combined with Toxoplasma serology for the presumptive diagnosis of focal central nervous system mass lesions in patients with AIDS. J Infect 2000; 40:274.</a></li><li><a class="nounderline abstract_t">Westwood TD, Hogan C, Julyan PJ, et al. Utility of FDG-PETCT and magnetic resonance spectroscopy in differentiating between cerebral lymphoma and non-malignant CNS lesions in HIV-infected patients. Eur J Radiol 2013; 82:e374.</a></li><li><a class="nounderline abstract_t">Lorberboym M, Wallach F, Estok L, et al. Thallium-201 retention in focal intracranial lesions for differential diagnosis of primary lymphoma and nonmalignant lesions in AIDS patients. J Nucl Med 1998; 39:1366.</a></li><li><a class="nounderline abstract_t">O'Doherty MJ, Barrington SF, Campbell M, et al. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med 1997; 38:1575.</a></li><li><a class="nounderline abstract_t">Conley FK, Jenkins KA, Remington JS. Toxoplasma gondii infection of the central nervous system. Use of the peroxidase-antiperoxidase method to demonstrate toxoplasma in formalin fixed, paraffin embedded tissue sections. Hum Pathol 1981; 12:690.</a></li><li><a class="nounderline abstract_t">Antinori A, Ammassari A, De Luca A, et al. Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. Neurology 1997; 48:687.</a></li><li><a class="nounderline abstract_t">Cinque P, Scarpellini P, Vago L, et al. Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction. AIDS 1997; 11:1.</a></li><li><a class="nounderline abstract_t">Nogui FL, Mattas S, Turcato Júnior G, Lewi DS. Neurotoxoplasmosis diagnosis for HIV-1 patients by real-time PCR of cerebrospinal fluid. Braz J Infect Dis 2009; 13:18.</a></li><li><a class="nounderline abstract_t">Mesquita RT, Ziegler AP, Hiramoto RM, et al. Real-time quantitative PCR in cerebral toxoplasmosis diagnosis of Brazilian human immunodeficiency virus-infected patients. J Med Microbiol 2010; 59:641.</a></li><li><a class="nounderline abstract_t">Dannemann B, McCutchan JA, Israelski D, et al. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med 1992; 116:33.</a></li><li><a class="nounderline abstract_t">Katlama C, De Wit S, O'Doherty E, et al. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 1996; 22:268.</a></li><li><a class="nounderline abstract_t">Nath A, Sinai AP. Cerebral Toxoplasmosis. Curr Treat Options Neurol 2003; 5:3.</a></li><li><a class="nounderline abstract_t">Jordan MK, Burstein AH, Rock-Kress D, et al. Plasma pharmacokinetics of sulfadiazine administered twice daily versus four times daily are similar in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48:635.</a></li><li><a class="nounderline abstract_t">Dedicoat M, Livesley N. Management of toxoplasmic encephalitis in HIV-infected adults (with an emphasis on resource-poor settings). Cochrane Database Syst Rev 2006; :CD005420.</a></li><li class="breakAll">Department of Health and Human Services. Notice of availability of pyrimethamine. https://aidsinfo.nih.gov/news/1604/notice-of-availability-of-pyrimethamine (Accessed on September 16, 2015).</li><li><a class="nounderline abstract_t">Torre D, Casari S, Speranza F, et al. Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group. Antimicrob Agents Chemother 1998; 42:1346.</a></li><li><a class="nounderline abstract_t">Béraud G, Pierre-François S, Foltzer A, et al. Cotrimoxazole for treatment of cerebral toxoplasmosis: an observational cohort study during 1994-2006. Am J Trop Med Hyg 2009; 80:583.</a></li><li><a class="nounderline abstract_t">Hernandez AV, Thota P, Pellegrino D, et al. A systematic review and meta-analysis of the relative efficacy and safety of treatment regimens for HIV-associated cerebral toxoplasmosis: is trimethoprim-sulfamethoxazole a real option? HIV Med 2017; 18:115.</a></li><li><a class="nounderline abstract_t">Jacobson JM, Hafner R, Remington J, et al. Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS. AIDS 2001; 15:583.</a></li><li><a class="nounderline abstract_t">Torres RA, Weinberg W, Stansell J, et al. Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Atovaquone/Toxoplasmic Encephalitis Study Group. Clin Infect Dis 1997; 24:422.</a></li><li><a class="nounderline abstract_t">Chirgwin K, Hafner R, Leport C, et al. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039. Clin Infect Dis 2002; 34:1243.</a></li><li><a class="nounderline abstract_t">Kovacs JA. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program. Lancet 1992; 340:637.</a></li><li><a class="nounderline abstract_t">Deen JL, von Seidlein L, Pinder M, et al. The safety of the combination artesunate and pyrimethamine-sulfadoxine given during pregnancy. Trans R Soc Trop Med Hyg 2001; 95:424.</a></li><li><a class="nounderline abstract_t">Bachmeyer C, Mouchnino G, Thulliez P, Blum L. Congenital toxoplasmosis from an HIV-infected woman as a result of reactivation. J Infect 2006; 52:e55.</a></li><li><a class="nounderline abstract_t">Lago EG, Conrado GS, Piccoli CS, et al. Toxoplasma gondii antibody profile in HIV-infected pregnant women and the risk of congenital toxoplasmosis. Eur J Clin Microbiol Infect Dis 2009; 28:345.</a></li><li><a class="nounderline abstract_t">Low incidence of congenital toxoplasmosis in children born to women infected with human immunodeficiency virus. European Collaborative Study and Research Network on Congenital Toxoplasmosis. Eur J Obstet Gynecol Reprod Biol 1996; 68:93.</a></li><li><a class="nounderline abstract_t">Minkoff H, Remington JS, Holman S, et al. Vertical transmission of toxoplasma by human immunodeficiency virus-infected women. Am J Obstet Gynecol 1997; 176:555.</a></li><li><a class="nounderline abstract_t">Duval X, Pajot O, Le Moing V, et al. Maintenance therapy with cotrimoxazole for toxoplasmic encephalitis in the era of highly active antiretroviral therapy. AIDS 2004; 18:1342.</a></li><li><a class="nounderline abstract_t">Katlama C, Mouthon B, Gourdon D, et al. Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group. AIDS 1996; 10:1107.</a></li><li><a class="nounderline abstract_t">Lejeune M, Miró JM, De Lazzari E, et al. Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis. Clin Infect Dis 2011; 52:662.</a></li><li><a class="nounderline abstract_t">Furco A, Carmagnat M, Chevret S, et al. Restoration of Toxoplasma gondii-specific immune responses in patients with AIDS starting HAART. AIDS 2008; 22:2087.</a></li><li><a class="nounderline abstract_t">Guex AC, Radziwill AJ, Bucher HC. Discontinuation of secondary prophylaxis for toxoplasmic encephalitis in human immunodeficiency virus infection after immune restoration with highly active antiretroviral therapy. Clin Infect Dis 2000; 30:602.</a></li><li><a class="nounderline abstract_t">Soriano V, Dona C, Rodríguez-Rosado R, et al. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2000; 14:383.</a></li><li><a class="nounderline abstract_t">Zeller V, Truffot C, Agher R, et al. Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis. Clin Infect Dis 2002; 34:662.</a></li><li><a class="nounderline abstract_t">Kirk O, Reiss P, Uberti-Foppa C, et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002; 137:239.</a></li><li><a class="nounderline abstract_t">Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009; 4:e5575.</a></li><li><a class="nounderline abstract_t">DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000; 133:447.</a></li><li><a class="nounderline abstract_t">French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000; 1:107.</a></li><li><a class="nounderline abstract_t">Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002; 81:213.</a></li><li><a class="nounderline abstract_t">Michelet C, Arvieux C, François C, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998; 12:1815.</a></li><li><a class="nounderline abstract_t">Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004; 38:1159.</a></li><li><a class="nounderline abstract_t">Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 2006; 57:167.</a></li><li><a class="nounderline abstract_t">Lawn SD. Immune reconstitution disease associated with parasitic infections following initiation of antiretroviral therapy. Curr Opin Infect Dis 2007; 20:482.</a></li><li><a class="nounderline abstract_t">Tremont-Lukats IW, Garciarena P, Juarbe R, El-Abassi RN. The immune inflammatory reconstitution syndrome and central nervous system toxoplasmosis. Ann Intern Med 2009; 150:656.</a></li><li><a class="nounderline abstract_t">Martin-Blondel G, Alvarez M, Delobel P, et al. Toxoplasmic encephalitis IRIS in HIV-infected patients: a case series and review of the literature. J Neurol Neurosurg Psychiatry 2011; 82:691.</a></li><li><a class="nounderline abstract_t">Aberg JA, Gallant JE, Ghanem KG, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis 2014; 58:e1.</a></li><li><a class="nounderline abstract_t">Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995; 332:693.</a></li><li><a class="nounderline abstract_t">Schneider MM, Hoepelman AI, Eeftinck Schattenkerk JK, et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group. N Engl J Med 1992; 327:1836.</a></li><li><a class="nounderline abstract_t">Antinori A, Murri R, Ammassari A, et al. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. AIDS 1995; 9:1343.</a></li><li><a class="nounderline abstract_t">Bucher HC, Griffith L, Guyatt GH, Opravil M. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15:104.</a></li><li><a class="nounderline abstract_t">Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med 1994; 120:932.</a></li><li><a class="nounderline abstract_t">Furrer H, Opravil M, Bernasconi E, et al. Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. Swiss HIV Cohort Study. Lancet 2000; 355:2217.</a></li><li><a class="nounderline abstract_t">Mussini C, Pezzotti P, Govoni A, et al. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study. J Infect Dis 2000; 181:1635.</a></li></ol></div><div id="topicVersionRevision">Topic 3710 Version 41.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1359410" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12715314" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989-1997.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1355579" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1520757" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Toxoplasmic encephalitis in AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1520757" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Toxoplasmic encephalitis in AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12439806" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevalence and predictors of Toxoplasma seropositivity in women with and at risk for human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8416410" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cats and toxoplasmosis risk in HIV-infected adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2386617" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Toxoplasma gondii serology in HIV-infected patients: the development of central nervous system toxoplasmosis in AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3006206" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Opportunistic infections in patients with AIDS: clues to the epidemiology of AIDS and the relative virulence of pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8537688" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11595976" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3216295" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Neuroepidemiology of acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22267718" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Toxoplasmosis hospitalizations in the United States, 2008, and trends, 1993-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10194081" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Incidence and risk factors of toxoplasmosis in a cohort of human immunodeficiency virus-infected patients: 1988-1995. HEMOCO and SEROCO Study Groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7984082" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Extracerebral toxoplasmosis in patients infected with HIV. A French National Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1557107" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Extreme elevations of serum lactic dehydrogenase differentiating pulmonary toxoplasmosis from Pneumocystis pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12718831" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The association of serum lactate dehydrogenase level with selected opportunistic infections and HIV progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8953067" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pulmonary toxoplasmosis in patients infected with human immunodeficiency virus: a French National Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15051204" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Diagnostic approaches to severe, atypical toxoplasmosis mimicking acute retinal necrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15051204" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Diagnostic approaches to severe, atypical toxoplasmosis mimicking acute retinal necrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8922803" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Toxoplasmosis of the spinal cord in a patient with AIDS: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8404165" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Septic shock due to toxoplasmosis in patients infected with the human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8302712" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Extracerebral toxoplasmosis in the acquired immunodeficiency syndrome (AIDS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2712059" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Evaluation of the policy of empiric treatment of suspected Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8460506" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Neurosurgical management of the acquired immunodeficiency syndrome. An update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6748191" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Toxoplasmic encephalitis in patients with acquired immune deficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8366923" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2324943" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The efficacy and clinical impact of brain imaging in neurologically symptomatic AIDS patients: a prospective CT/MRI study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2213162" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Use of CT and MR imaging to distinguish intracranial lesions and to define the need for biopsy in AIDS patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9924465" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Magnetic resonance imaging, thallium-201 SPET scanning, and laboratory analyses for discrimination of cerebral lymphoma and toxoplasmosis in AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10908023" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : SPECT thallium-201 combined with Toxoplasma serology for the presumptive diagnosis of focal central nervous system mass lesions in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23578921" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Utility of FDG-PETCT and magnetic resonance spectroscopy in differentiating between cerebral lymphoma and non-malignant CNS lesions in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9708509" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Thallium-201 retention in focal intracranial lesions for differential diagnosis of primary lymphoma and nonmalignant lesions in AIDS patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9379195" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : PET scanning and the human immunodeficiency virus-positive patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7026410" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Toxoplasma gondii infection of the central nervous system. Use of the peroxidase-antiperoxidase method to demonstrate toxoplasma in formalin fixed, paraffin embedded tissue sections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9065549" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9110070" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19578625" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Neurotoxoplasmosis diagnosis for HIV-1 patients by real-time PCR of cerebrospinal fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20150319" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Real-time quantitative PCR in cerebral toxoplasmosis diagnosis of Brazilian human immunodeficiency virus-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1727093" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8838183" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12521559" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cerebral Toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14742225" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Plasma pharmacokinetics of sulfadiazine administered twice daily versus four times daily are similar in human immunodeficiency virus-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16856096" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Management of toxoplasmic encephalitis in HIV-infected adults (with an emphasis on resource-poor settings).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16856096" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Management of toxoplasmic encephalitis in HIV-infected adults (with an emphasis on resource-poor settings).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9624473" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19346380" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cotrimoxazole for treatment of cerebral toxoplasmosis: an observational cohort study during 1994-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27353303" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A systematic review and meta-analysis of the relative efficacy and safety of treatment regimens for HIV-associated cerebral toxoplasmosis: is trimethoprim-sulfamethoxazole a real option?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11316995" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9114194" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Atovaquone/Toxoplasmic Encephalitis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11941551" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1355212" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11579889" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The safety of the combination artesunate and pyrimethamine-sulfadoxine given during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16043225" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Congenital toxoplasmosis from an HIV-infected woman as a result of reactivation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18855029" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Toxoplasma gondii antibody profile in HIV-infected pregnant women and the risk of congenital toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8886688" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Low incidence of congenital toxoplasmosis in children born to women infected with human immunodeficiency virus. European Collaborative Study and Research Network on Congenital Toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9077606" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Vertical transmission of toxoplasma by human immunodeficiency virus-infected women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15362670" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Maintenance therapy with cotrimoxazole for toxoplasmic encephalitis in the era of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8874627" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21292671" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18832872" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Restoration of Toxoplasma gondii-specific immune responses in patients with AIDS starting HAART.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10722454" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Discontinuation of secondary prophylaxis for toxoplasmic encephalitis in human immunodeficiency virus infection after immune restoration with highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10770540" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11810599" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12186514" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19440326" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10975963" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11737333" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11997718" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9792382" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Opportunistic infections occurring during highly active antiretroviral treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15095223" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Immune reconstitution in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16354748" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Immune reconstitution inflammatory syndrome: more answers, more questions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17762781" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Immune reconstitution disease associated with parasitic infections following initiation of antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19414855" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The immune inflammatory reconstitution syndrome and central nervous system toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20660912" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Toxoplasmic encephalitis IRIS in HIV-infected patients: a case series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24235263" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7854375" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1360145" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8605054" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9241108" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8172439" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Prophylaxis for opportunistic infections in patients with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10881897" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. Swiss HIV Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10823763" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
